Baader Bank Aktiengesellschaft Has $1.83 Million Stock Position in Stryker Co. (NYSE:SYK)

Baader Bank Aktiengesellschaft lifted its stake in Stryker Co. (NYSE:SYK - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,085 shares of the medical technology company's stock after purchasing an additional 1,031 shares during the period. Baader Bank Aktiengesellschaft's holdings in Stryker were worth $1,831,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. Parnassus Investments LLC bought a new position in Stryker in the third quarter valued at approximately $762,798,000. International Assets Investment Management LLC boosted its stake in Stryker by 66,967.5% in the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock valued at $308,433,000 after acquiring an additional 852,496 shares during the last quarter. RTW Investments LP bought a new position in Stryker in the third quarter valued at approximately $143,392,000. State Street Corp boosted its stake in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after acquiring an additional 316,404 shares during the last quarter. Finally, FMR LLC boosted its stake in Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock valued at $2,639,725,000 after acquiring an additional 215,782 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Up 0.1 %

NYSE SYK traded up $0.54 on Thursday, reaching $391.61. The company had a trading volume of 775,043 shares, compared to its average volume of 1,552,460. The company's fifty day moving average is $376.55 and its 200-day moving average is $362.18. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market capitalization of $149.29 billion, a price-to-earnings ratio of 41.96, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter in the previous year, the firm posted $3.46 EPS. On average, research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's payout ratio is 36.01%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SYK. Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Tuesday, January 7th. Evercore ISI boosted their price target on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Finally, Citigroup boosted their price target on shares of Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and a consensus price target of $416.40.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.